Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia

Molecular Diagnosis and Therapy

Volumn 17, Issue 5, 2013, Pages 299-309

  Shabana, Mona F ^a   Mishriki, Amal A ^b   Issac, Marianne Samir M ^b   Bakhoum, Sameh W G ^b  

^a Fayoum University   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; EGYPT; FEMALE; GENE INTERACTION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; TREATMENT RESPONSE; WILD TYPE;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EGYPT; FEMALE; GENETIC VARIATION; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PYRROLES; RISK FACTORS; SEX CHARACTERISTICS; TRIGLYCERIDES;

EID: 84885171127     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0038-3     Document Type: Article

References (46)

1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52.
2. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35(1):1-10.
3. Bercovich Dani, Friedlander Yechiel, Korema Sigal, et al. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis. 2006;185:97-107.
4. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet. 2001;2:9-39.
5. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin Lipidol. 2007;18:409-14.
6. Rodrigues AC, Rebecchi IMM, Bertolami MC, et al. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res. 2005;38:1389-97.
7. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
8. Hamidovic A, Hahn K, Kolesar J. Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Practice. 2010;16:39-44.
9. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157-81.
10. Oshiro C, Mangravite L, Klein T, et al. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010;20:211-6.
11. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy - a genome wide study. N Engl J Med. 2008;359:789-99.
12. Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001;276:35669-75.
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
15. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169-74.
16. Deeken JF, Figg WD, Bates SE, et al. Toward individualized treatment: predication of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs. 2007;18:111-26.
17. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-49.
18. Voora D, Shah SH, Reed CR, et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet. 2008;1(2):100-6.
19. Rebecchi MM, Rodrigues AC, Arazi SS, et al. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol. 2009;77:66-75.
20. Rodrigues AC, Perin PM, Purim SG, et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A > G variant is determinant of increased atorvastatin response. Int J Mol Sci. 2011;12:5815-27.
21. Pedro-Botet J, Schaefer EJ, Arkema RB, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158:183-93.
22. Kajinami K, Brousseau ME, Lamon-Fava S, et al. Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis. 2005;178:331-8.
23. Sakabe K, Fukuda N, Fukuda Y, et al. Gender differences in short-term effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function. Nutr Metabol Cardiovasc Dis. 2008;18:182-8.
24. Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141-60.
25. Rosales A, Alvear M, Cuevas A, et al. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clin Chim Acta. 2012;413(3-4):495-501.
26. Elise Jeannesson, Gérard Siest, Bérangère Bastien, et al. Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clin Chim Acta. 2009;403:198-202.
27. Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci USA. 2002;99:10347-52.
28. Kajinami K, Brousseau ME, Ordovas JM, et al. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol. 2004;93:1046-50.
29. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-8.
30. Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genom. 2005;15:693-704.
31. Rodrigues AC, Curi R, Britto LR, et al. Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim Biophys Acta. 2006;1760:1866-73.
32. Mega JL, Morrow DA, Brown A, et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009;29:1310-5.
33. Miao M, Mak, Valiant WL, Tomlinson B. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidemia. Pharmacogenet Genomics. 2012;22(11):803-6. doi: 10.1097/FPC.0b013e3283557c98.
34. Donnelly LA, Doney ASF, Tavendale R, et al. Common non-synonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther. 2011;89(2):210-6.
35. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
36. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359(8):789-99.
37. Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005;5:352-8.
38. Han YH, Busler D, Hong Y, et al. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters. Drug Metab Dispos. 2010;38:1072-82.
39. Kokaze A, Ishikawaa M, Matsunaga N, et al. Longevity-associated mitochondrial DNA 5178 A/C polymorphism modulates effects of daily drinking and cigarette consumption on serum triglyceride levels in middle-aged Japanese men. Exp Gerontol. 2003;38:1071-6.
40. Hoenig MR, Sellke FW. Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. Atherosclerosis. 2010;211:260-5.
41. Mitsios JV, Papathanasiou AI, Rodis FI. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation. 2004;109:1335-8.
42. Ozbilen S, Eren MA, Turan MN, et al. The impact of carvedilol and metoprolol on serum lipid concentrations and symptoms in patients with hyperthyroidism. Endocr Res. 2012;37(3):117-23.
43. Wen J, Xiong Y. OATP1B1 388A > G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther. 2010;35:99-104.
44. Akaoa H, Polisecki E, Kajinami K, et al. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis. 2012;220:413-7.
45. Hamilton RJ, Goldberg KC, Platz EA, et al. The influence of statin medications on prostate specific antigen levels. J Natl Cancer Inst. 2008;100:1511-8.
46. Paulo CJ, Santos L, Gagliardi AM, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2012;68:273-9.